Evidence map›Paper›PMID 40371939›Full record

ArticleEuropean journal of clinical investigation2025

Mesenchymal stem cell-mediated mitochondrial transfer regulates the fate of B lymphocytes.

Veronika Somova, Natalie Jaborova, Bianka Porubska, Daniel Vasek, Natalie Fikarova, Martin Prevorovsky, Zuzana Nahacka, Jiri Neuzil, Magdalena Krulova

Abstract read
In one paragraph

Article in European journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Veronika SomovaDepartment of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic.
Natalie JaborovaDepartment of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic.
Bianka PorubskaDepartment of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic.
Daniel VasekDepartment of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic.
Natalie FikarovaDepartment of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic.
Martin PrevorovskyDepartment of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic.
Zuzana NahackaLaboratory of Molecular Therapy, Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech Republic.
Jiri NeuzilLaboratory of Molecular Therapy, Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech Republic.
Magdalena KrulovaDepartment of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic.ORCID https://orcid.org/0000-0003-3622-376X

Funding

Grantová Agentura České Republiky 21-04607XGrantová Agentura, Univerzita Karlova 98723Univerzita Karlova v Praze
6 · The paper itself

Abstract

backgroundMitochondrial transfer is becoming recognized as an important immunomodulatory mechanism used by mesenchymal stem cells (MSCs) to influence immune cells. While effects on T cells and macrophages have been documented, the influence on B cells remains unexplored. This study investigates the modulation of B lymphocyte fate by MSC-mediated mitochondrial transfer.

methodsMSCs labelled with MitoTracker dyes or derived from mito::mKate2 transgenic mice were co-cultured with splenocytes. Flow cytometry assessed mitochondrial transfer, reactive oxygen species (ROS) levels, apoptosis and mitophagy. Glucose uptake was measured using the 2-NBDG assay. RNA sequencing analysed gene expression changes in CD19+ mitochondria recipients and nonrecipients. Pathway analysis identified affected processes. In an LPS-induced inflammation model, mito::mKate2 MSCs were administered, and B cells from different organs were analysed for mitochondrial uptake and phenotypic changes. MSC-derived mitochondria were also isolated to confirm uptake by FACS-sorted CD19+ cells.

resultsMSCs transferred mitochondria to CD19+ cells, though less than to other immune cells. Transfer correlated with ROS levels and mitophagy induction. Mitochondria were preferentially acquired by activated B cells, as indicated by increased CD69 expression and glycolytic activity. Bidirectional transfer occurred, with immune cells exchanging dysfunctional mitochondria for functional ones. CD19+ recipients exhibited increased viability, proliferation and altered gene expression, with upregulated cell division genes and downregulated antigen presentation genes. In vivo, mitochondrial acquisition reduced B cell activation and inflammatory cytokine production. Pre-sorted B cells also acquired isolated mitochondria, exhibiting a similar anti-inflammatory phenotype.

conclusionsThese findings highlight mitochondrial trafficking as a key MSC-immune cell interaction mechanism with immunomodulatory therapeutic potential.

Indexed as

B-LymphocytesMesenchymal Stem CellsMitochondriaAnimalsAntigens, CDAntigens, CD19Antigens, Differentiation, T-LymphocyteApoptosisCD69 AntigensCoculture TechniquesLectins, C-TypeLymphocyte ActivationMiceMice, TransgenicMitophagyReactive Oxygen SpeciesAntigens, CDAntigens, CD19Antigens, Differentiation, T-LymphocyteCD69 AntigensLectins, C-TypeReactive Oxygen SpeciesB cellimmunoregulationmesenchymal stem cellmetabolismmitochondria

Identifiers

PMID40371939
PMCPMC12434451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.